Celonic Group Integrates Merck’s Breez Platform to Boost Bioprocessing Efficiency

• Celonic Group has integrated Merck’s Breez micro-bioreactor platform into its process development.

• The technology will enhance monoclonal antibody (mAb) manufacturing by enabling scalable perfusion-based bioprocessing.

Celonic Group has announced the integration of Merck’s Breez micro-bioreactor platform into its process development workflows. The Swiss-based CDMO aims to enhance its capabilities in monoclonal antibody (mAb) manufacturing by leveraging Breez for scalable perfusion-based bioprocessing.

The Breez 2 mL micro-bioreactor is a fully automated, functionally closed system designed for continuous perfusion cell culture. By incorporating this technology, Celonic expects to accelerate upstream process optimisation, lower production costs, and improve operational efficiency.

“This technology integration marks a significant milestone in our pursuit of innovative bioprocessing solutions,” said Samanta Cimitan, Ph.D., CEO of Celonic Group. “By leveraging the Breez™ platform, we can enhance our ability to develop and manufacture biologics with the aim of increasing productivity, reducing the cost of goods per gram, ultimately benefiting our clients and patients worldwide.”

With this integration, Celonic strengthens its position as a CDMO offering advanced biologics development and manufacturing solutions. The company aims to provide efficient and cost-effective contract manufacturing services for global pharmaceutical and biotech partners.